Dova Pharmaceuticals, Inc. announced the commercial availability of DOPTELET (avatrombopag) for treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. In June 2019, the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the use of DOPTELET to include this indication. DOPTELET is also FDA-approved for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. The European Commission has also granted marketing authorization for DOPTELET for the treatment of severe thrombocytopenia in adult patients with CLD who are scheduled to undergo an invasive procedure.